CN1231216C - 门冬氨酸洛美沙星粉剂及其制备方法 - Google Patents
门冬氨酸洛美沙星粉剂及其制备方法 Download PDFInfo
- Publication number
- CN1231216C CN1231216C CN 03140207 CN03140207A CN1231216C CN 1231216 C CN1231216 C CN 1231216C CN 03140207 CN03140207 CN 03140207 CN 03140207 A CN03140207 A CN 03140207A CN 1231216 C CN1231216 C CN 1231216C
- Authority
- CN
- China
- Prior art keywords
- aspartic acid
- powder
- test
- preparation
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000843 powder Substances 0.000 title claims abstract description 78
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 title claims abstract description 60
- 235000003704 aspartic acid Nutrition 0.000 title claims abstract description 60
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 20
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 title abstract description 20
- 229960002422 lomefloxacin Drugs 0.000 title abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 52
- 239000007924 injection Substances 0.000 claims description 38
- 238000002347 injection Methods 0.000 claims description 38
- 238000001914 filtration Methods 0.000 claims description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- 239000008103 glucose Substances 0.000 claims description 16
- 238000004090 dissolution Methods 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 11
- 239000012982 microporous membrane Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 7
- 239000002798 polar solvent Substances 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 7
- 150000001299 aldehydes Chemical class 0.000 abstract description 6
- 150000001720 carbohydrates Chemical class 0.000 abstract description 6
- 150000002576 ketones Chemical class 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 3
- 230000007423 decrease Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 75
- 238000012360 testing method Methods 0.000 description 70
- 229940079593 drug Drugs 0.000 description 62
- 229940090044 injection Drugs 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 239000000047 product Substances 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 21
- 239000007788 liquid Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 241000700199 Cavia porcellus Species 0.000 description 14
- 239000002158 endotoxin Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 206010002198 Anaphylactic reaction Diseases 0.000 description 11
- 206010018910 Haemolysis Diseases 0.000 description 11
- 208000003455 anaphylaxis Diseases 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- 229930195725 Mannitol Natural products 0.000 description 8
- 230000036783 anaphylactic response Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 239000000594 mannitol Substances 0.000 description 8
- 235000010355 mannitol Nutrition 0.000 description 8
- 238000012856 packing Methods 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 206010070834 Sensitisation Diseases 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 7
- 230000008588 hemolysis Effects 0.000 description 7
- 230000002949 hemolytic effect Effects 0.000 description 7
- 230000008313 sensitization Effects 0.000 description 7
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229960001699 ofloxacin Drugs 0.000 description 6
- 102000002322 Egg Proteins Human genes 0.000 description 5
- 108010000912 Egg Proteins Proteins 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 229940093181 glucose injection Drugs 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 239000002932 luster Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 239000002547 new drug Substances 0.000 description 5
- 229960001180 norfloxacin Drugs 0.000 description 5
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 5
- 210000004681 ovum Anatomy 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000004088 simulation Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000005180 public health Effects 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- WWJBDSBGLBEFSH-UHFFFAOYSA-N 2-(4-methoxyphenyl)azepane Chemical compound C1=CC(OC)=CC=C1C1NCCCCC1 WWJBDSBGLBEFSH-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000005496 eutectics Effects 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 229960003814 lomefloxacin hydrochloride Drugs 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 238000011027 product recovery Methods 0.000 description 3
- 239000008354 sodium chloride injection Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 241000239222 Tachypleus Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000006303 photolysis reaction Methods 0.000 description 2
- 230000015843 photosynthesis, light reaction Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 238000005491 wire drawing Methods 0.000 description 2
- YCOJCBAVYZZKRS-WNQIDUERSA-N (2s)-2-aminobutanedioic acid;1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 YCOJCBAVYZZKRS-WNQIDUERSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- -1 amino acid salts Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002771 monosaccharide derivatives Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical class [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical class [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005092 sublimation method Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
处方序号 | A | B | C | D |
门冬氨酸洛美沙星 | 138.4g | 138.4g | 138.4g | 138.4g |
葡萄糖 | 0 | 50g | 100g | 150g |
加注射用水后体积 | 2000ml | 2000ml | 2000ml | 2000ml |
外观性状 | 淡黄色粉末、萎缩。 | 类白色块状物,稍萎缩。 | 类白色疏松块状物,体积基本无变化。 | 类白色疏松块状物,体积基本无变化。 |
酸度值 | 5.00 | 4.99 | 4.98 | 4.92 |
澄清度与颜色 | 澄明<YG1 | 澄明<YG1 | 澄明<YG1 | 澄明<YG1 |
溶解速度 | 溶解较慢 | 溶解较快 | 溶解快速 | 溶解快速 |
处方序号 | E | F | G |
门冬氨酸洛美沙星 | 138.4g | 138.4g | 138.4g |
甘露醇 | 50g | 100g | 150g |
加注射用水后体积 | 2000ml | 2000ml | 2000ml |
外观性状 | 类白色块状物,稍萎缩。 | 类白色块状物,体积基本无变化。 | 类白色疏松块状物,体积基本无变化。 |
酸度值 | 5.00 | 4.97 | 4.96 |
澄清度与颜色 | 澄明<YG1 | 澄明<YG1 | 澄明<YG1 |
溶解速度 | 溶解较快 | 溶解较快 | 溶解较快 |
供试品样号 | 供试品管x2 | 阳性对照管 | 阴性对照管 | 供试品阳性对照管 |
20000401 | -/- | + | - | + |
20000402 | -/- | + | - | + |
20000403 | -/- | + | - | + |
样号 | 阳性菌对照 | 阴性对照 | 需氧菌 | 厌氧菌 | 真菌 |
20000401 | + | - | - | - | - |
20000402 | + | - | - | - | - |
20000403 | + | - | - | - | - |
考察项目 | 5%葡萄糖注射 | 0.9%氯化钠注射液 | 碳酸氢钠注射液 |
混合前外观 | 无色澄明液体 | 无色澄明液体 | 无色澄明液体 |
PH值 | 4.86 | 4.98 | 8.3 |
混合后外观 | |||
混合后0hr | 微黄澄明液体 | 微黄澄明液体 | 产生大量细小气泡,并产生浑浊 |
混合后2hr | 微黄澄明液体 | 微黄澄明液体 | 有沉淀物产生 |
混合后4hr | 微黄澄明液体 | 微黄澄明液体 | 有沉淀物产生 |
混合后pH值 | |||
混合后0hr | 4.9 | 4.98 | 因产生浑浊无须测定 |
混合后2hr | 4.92 | 4.97 | / |
混合后4hr | 4.91 | 4.98 | / |
吸收度 | |||
混合后0hr | 0.614 | 0.606 | / |
混合后2hr | 0.616 | 0.606 | / |
混合后4hr | 0.612 | 0.609 | / |
放置时间(天) | 外观色泽 | 酸度 | 澄明度与颜色 | 标示含量(%) | 有关物质(%) |
0 | 微黄色疏松块状物 | 4.97 | 澄明<YG2 | 99.4 | 0.23 |
5 | 微黄色疏松块状物 | 4.96 | 澄明<YG2 | 98.4 | 0.19 |
10 | 微黄色疏松块状物 | 4.96 | 澄明<YG2 | 97.4 | 0.33 |
放置时间(天) | 外观色泽 | 酸度 | 澄明度与颜色 | 吸湿率(%) | 标示含量(%) | 有关物质(%) |
0 | 微黄色疏松块状物 | 4.97 | 澄明<YG2 | 0 | 99.4 | 0.23 |
5 | 微黄色疏松块状物,外沿吸湿 | 4.95 | 澄明<YG2 | 17.0 | 100.0 | 0.30 |
10 | 微黄色疏松块状物,吸湿 | 4.94 | 澄明<YG2 | 26.3 | 98.1 | 0.47 |
放置时间(天) | 外观色泽 | 酸度 | 澄明度与颜色 | 吸湿率(%) | 标示含量(%) | 有关物质(%) |
0 | 微黄色疏松块状物 | 4.97 | 澄明<YG2 | 0 | 99.4 | 0.23 |
5 | 微黄色疏松块状物,略吸湿 | 4.97 | 澄明<YG2 | 11.3 | 97.6 | 0.34 |
10 | 微黄色疏松块状物,吸湿 | 4.95 | 澄明<YG2 | 17.6 | 98.8 | 0.30 |
放置时间(天) | 外观色泽 | 酸度 | 澄明度与颜色 | 标示含量(%) | 有关物质(%) |
0 | 微黄色疏松块状物 | 4.97 | 澄明<YG2 | 99.4 | 0.23 |
5 | 微黄色疏松块状物 | 4.96 | 澄明<YG2 | 98.5 | 0.34 |
10 | 微黄色疏松块状物 | 4.98 | 澄明<YG2 | 98.3 | 0.55 |
小白鼠批次号 | 注射小时及反应死亡数 | |||
12 | 24 | 36 | 48 | |
1 | 0 | 0 | 0 | 0 |
2 | 0 | 0 | 0 | 0 |
3 | 0 | 0 | 0 | 0 |
4 | 0 | 0 | 0 | 0 |
5 | 0 | 0 | 0 | 0 |
反应级数 | 反应症状 |
0 | 无明显反应 |
1 | 只有轻微抓鼻、颤抖或竖毛 |
2 | 有几次咳嗽、抓鼻、颤抖或竖毛 |
3 | 多次或连续咳嗽、伴有呼吸困难或痉挛、抽搐等 |
4 | 痉挛、抽搐、大小便失禁、休克死亡 |
试液(ml) | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
供试品溶液 | 0.1 | 0.2 | 0.3 | 0.4 | 0.5 | - | - |
生理盐水 | 2.4 | 2.3 | 2.2 | 2.1 | 2.0 | 2.5 | - |
蒸馏水 | - | - | - | - | - | - | 2.5 |
2%红细胞混悬液 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
时间(h) | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
0.5 | - | - | - | - | - | - | + |
1 | - | - | - | - | - | - | + |
2 | - | - | - | - | - | - | + |
3 | - | - | - | - | - | - | + |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03140207 CN1231216C (zh) | 2003-08-19 | 2003-08-19 | 门冬氨酸洛美沙星粉剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03140207 CN1231216C (zh) | 2003-08-19 | 2003-08-19 | 门冬氨酸洛美沙星粉剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1488349A CN1488349A (zh) | 2004-04-14 |
CN1231216C true CN1231216C (zh) | 2005-12-14 |
Family
ID=34155248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03140207 Expired - Fee Related CN1231216C (zh) | 2003-08-19 | 2003-08-19 | 门冬氨酸洛美沙星粉剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1231216C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101157684B (zh) * | 2006-12-05 | 2010-06-02 | 李青 | 门冬氨酸洛美沙星水合物及其制备和用途 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102276582A (zh) * | 2011-08-10 | 2011-12-14 | 天津市汉康医药生物技术有限公司 | 门冬氨酸洛美沙星化合物 |
-
2003
- 2003-08-19 CN CN 03140207 patent/CN1231216C/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101157684B (zh) * | 2006-12-05 | 2010-06-02 | 李青 | 门冬氨酸洛美沙星水合物及其制备和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN1488349A (zh) | 2004-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8791060B2 (en) | Composition and use of phyto-percolate for treatment of disease | |
CN102160852A (zh) | 一种布洛芬注射液及制备方法 | |
EP1954800A2 (en) | Composition and use of phyto-percolate for treatment of disease | |
CN1915986A (zh) | 一种高纯度的丹参酮iia磺酸钠、制备方法及其制剂 | |
CN1231216C (zh) | 门冬氨酸洛美沙星粉剂及其制备方法 | |
CN1215836C (zh) | 注射用盐酸索他洛尔及其制备方法 | |
CN1686460A (zh) | 一种清开灵输液及其制备方法 | |
CN1868460A (zh) | 注射用盐酸多西环素冻干制剂及其制备工艺 | |
CN1771992A (zh) | 一种脑提取物及其制备方法和用途 | |
CN1732934A (zh) | 注射用盐酸倍他司汀冻干粉针剂及其制备方法 | |
CN1397567A (zh) | 螺旋藻多糖及其提取方法和在制备升白和抗癌药物中的用途 | |
RU2526571C1 (ru) | Инъекционный препарат для повышения спермопродукции человека и способ его применения | |
CN1048879C (zh) | 一种治疗原发性肾小球疾病及乳糜尿的药物及其制备方法 | |
CN1218704C (zh) | 注射用藻酸双酯钠及其制备方法 | |
CN1751691A (zh) | 天麻素静脉小容量注射剂及其制备方法 | |
CN1836651A (zh) | 左旋舒必利注射剂的制备方法 | |
CN101837061B (zh) | 山楂叶及其提取物的制药用途 | |
CN1634413A (zh) | 一种勒马回注射制剂及其制备方法 | |
CN1586620A (zh) | 聚明胶肽注射液及其制备方法 | |
CN1939328A (zh) | 葛根素注射用制剂 | |
CN1257713C (zh) | 盐酸氟桂利嗪注射液及其制备方法 | |
CN1613453A (zh) | 一种阿奇霉素注射液及制备方法 | |
CN1403084A (zh) | 更昔洛韦注射液及其生产方法 | |
CN107793495A (zh) | 皱皮木瓜多糖及其制备方法和应用 | |
CN102772373B (zh) | 一种注射用酒石酸长春瑞滨粉针剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: YANGPU WITHUB MEDICAL CO., LTD. Free format text: FORMER NAME: YANGPU HUAHAI MEDICAL MATERIAL CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: Yangpu Economic Development Zone of Hainan Province, Hong Kong Road Jinlan mall A204 room Patentee after: Yangpu Huigu Pharmaceutical Co., Ltd. Address before: No. 5, industrial zone, Yangpu Economic Development Zone, Hainan, Danzhou Patentee before: Huahai Medicine Material Co., Ltd., Yangpu |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Fuhua Pharmaleutical Industry Co., Ltd., Shanghai Assignor: Yangpu Huigu Pharmaceutical Co., Ltd. Contract fulfillment period: 2009.10.27 to 2015.10.27 Contract record no.: 2009310000297 Denomination of invention: Aspartic acid lomefloxacin powder and preparing method thereof Granted publication date: 20051214 License type: Exclusive license Record date: 20091116 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.10.27 TO 2015.10.27; CHANGE OF CONTRACT Name of requester: SHANGHAI FUDAN FUHUA PHARMACEUTICAL CO., LTD. Effective date: 20091116 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Fuhua Pharmaleutical Industry Co., Ltd., Shanghai Assignor: Yangpu Huigu Pharmaceutical Co., Ltd. Contract record no.: 2009310000297 Date of cancellation: 20170815 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20040414 Assignee: Fuhua Pharmaleutical Industry Co., Ltd., Shanghai Assignor: Yangpu Huigu Pharmaceutical Co., Ltd. Contract record no.: 2017310000045 Denomination of invention: Aspartic acid lomefloxacin powder and preparing method thereof Granted publication date: 20051214 License type: Exclusive License Record date: 20170816 |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051214 Termination date: 20190819 |